Dr Abdul Mannan: Clonal Haematopoiesis – More Common, More Complex
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“Clonal Haematopoiesis: More Commoon. More Complex. More Relevant Than We Realised.
Today I shared an updated infographic on Clonal Haematopoiesis – a topic that has quietly moved from academic curiosity to something every clinician should have on their radar.
What struck me most while putting this together is how far beyond cancer this story goes.
For years, we framed CHIP and CCUS as “pre-leukaemic”. The problem is… that’s only half the picture.
These tiny clones behave like slow-burning fires.
They sit in the marrow, send out inflammatory signals, and nudge the immune system into a persistent “low-grade storm”. The result?
Higher rates of ischaemic heart disease, stroke, and heart failure, particularly with mutations like TET2, DNMT3A, JAK2 V617F.
And in the real world, that’s often where the danger lies.
The infographic breaks it down clearly:
- CHIP – mutation present, blood counts normal
- CCUS – mutation + sustained cytopenias
- High-risk CCUS – where leukaemic transformation risk climbs
- VEXAS – the perfect reminder that a “clonal process” doesn’t always behave like a cancer
It also highlights a simple monitoring approach that doesn’t overwhelm patients or clinics:
- CHIP → annual CBC
- CCUS → every 3–6 months
- High-risk patterns → consider marrow assessment and closer follow-up
As haematologists, we’re used to dealing with rapid, dramatic conditions.
Clonal haematopoiesis is the opposite.
Quiet. Slow. Easy to miss.
Until it isn’t.
If you’re teaching trainees, reviewing cardiology referrals, or running a general haematology clinic, this is a space worth understanding.
I’ll keep sharing more simplified, practical resources like this – to make the science accessible not just for exam preparation, but for real clinical decision-making.
Happy to discuss cases, interpretations, and grey areas.
The dialogue around this is just beginning.”
Follow the latest with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women